Mereo BioPharma’s Post

A comprehensive study of the healthcare journey of people with osteogenesis imperfecta (OI) in 13 European countries has revealed significant challenges, from delayed diagnoses and misdiagnoses to inconsistent care approaches. These gaps highlight the need for greater awareness and support for those living with OI. A key finding underscores the vital role of multidisciplinary care teams - geneticists, endocrinologists, orthopaedic surgeons, and more - in providing coordinated, lifelong support. However, many people face difficulties accessing this essential care, especially during the transition from paediatric to adult services, where coordinated care management can be challenging. Beyond medical care, the study also draws attention to the psychosocial toll on people with OI and their families. The authors, including Ingunn Westerheim, VALERIE CORMIER DAIRE and Richard Keen, conclude that advocacy, awareness, and the development of standardised guidelines are important for improving the quality of life for those with OI, from diagnosis to adulthood. The publication can be viewed in full in the Orphanet Journal of Rare Diseases: https://lnkd.in/ewgMazPQ #OsteogenesisImperfecta #OI

Our business is publishing

Our business is publishing

springer.com

To view or add a comment, sign in

Explore topics